| |
|
|
 |
| |
|
|
| |
|
|
| |
|
|
| |
|
 |
| | |
:: | | |
:: | | |
:: | | |
:: | | |
:: | | |
:: | | |
:: | | |
:: | | |
:: | | |
:: | |
|
|
| |
|
|
|
|
|
| |
|
|
RNAi Therapy & Clinical Trials
Sponsored Links
- Alnylam Pharmaceuticals, Inc.
- Alnylam was founded by Nobel Laureate Phillip Sharp, Thomas Tuschl et al. The company's current capabilities are supporting the development of Direct RNAi™ therapeutics. These products are designed to be administered directly to sites of diseases in various parts of the body, such as the eye, the brain or the lungs.
- Calando Pharmaceuticals
- Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics and develops nanoparticle therapeutics that use sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA. CALAA-01, the company's leading drug candidate for treating cancer, is in phase II trial.
- Silence Therapeutics
- Silence Therapeutics has several RNAi drugs in phase I and II trials for treating diabetic macular edema, age-related macular degeneration, acute kidney injury, and cancers.
- Sirna Therapeutics, Inc
- The company's researchers are developing siRNAs targeting the VEG-F (vascular endothelial growth factor) for the treatment of macular degeneration, the leading cause of blindness, and hepatitis C virus.
|
